<DOC>
	<DOC>NCT02786095</DOC>
	<brief_summary>This study is prospective Cohort study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is all patients with atrial fibrillation who visit hospital. The purpose is to analyze complication, composite outcome (all cause mortality, hospitalization, the incidence of stroke, heart failure and cardiovascular event (MACE)) according to the 1) the use of anti-arrhythmic drugs (AADs), 2) use of medication for rate control (beta blocker, calcium channel blocker and digoxin) and 3) use of anticoagulation agents (warfarin, coumadin, an NOAC)</brief_summary>
	<brief_title>Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>patients with atrial fibrillation patients with age more than 19 patients who agree with study inclusion patients who do not agree with study inclusion patients with age less than 19 Pregnancy, Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>anti arrhythmic drug</keyword>
	<keyword>NOAC</keyword>
	<keyword>warfarin</keyword>
	<keyword>coumadin</keyword>
</DOC>